King Luther Capital Management Corp Has $45,000 Stock Holdings in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI)

King Luther Capital Management Corp decreased its stake in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) by 59.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,000 shares of the company’s stock after selling 48,129 shares during the quarter. King Luther Capital Management Corp’s holdings in Rani Therapeutics were worth $45,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Stifel Financial Corp raised its stake in shares of Rani Therapeutics by 100.4% in the 3rd quarter. Stifel Financial Corp now owns 269,768 shares of the company’s stock valued at $583,000 after purchasing an additional 135,148 shares during the period. Geode Capital Management LLC raised its position in shares of Rani Therapeutics by 14.3% in the third quarter. Geode Capital Management LLC now owns 172,261 shares of the company’s stock valued at $372,000 after purchasing an additional 21,527 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new stake in Rani Therapeutics during the fourth quarter worth approximately $37,000. 30.19% of the stock is currently owned by institutional investors and hedge funds.

Rani Therapeutics Trading Up 3.4 %

Shares of RANI stock opened at $1.51 on Friday. The stock has a market capitalization of $86.51 million, a price-to-earnings ratio of -1.42 and a beta of 0.14. The company’s fifty day simple moving average is $1.49 and its two-hundred day simple moving average is $1.95. Rani Therapeutics Holdings, Inc. has a 1 year low of $1.24 and a 1 year high of $8.75. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Canaccord Genuity Group reissued a “buy” rating and set a $9.00 price target on shares of Rani Therapeutics in a report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Rani Therapeutics in a research note on Friday, February 7th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.33.

Rani Therapeutics Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.